Tirzepatide for PCOS: what the evidence actually supports

What did @sarah_with_pcos actually say?

Sarah, a 41-year-old woman with PCOS who has been on a GLP-1 medication for one year, is responding to a follower who stopped seeing results after a dose increase. Her core argument has two parts: first, give a new dose at least a month before judging it, especially if your cycle affects how the medication feels. Second, and this is where it gets interesting, she says changing your injection location can produce a "really big difference" in how your body responds to the medication.

She also describes something a lot of GLP-1 users report: the week before a period, hunger returns hard. "The medication can't even touch it," she says. She frames these observations as patterns she has noticed personally and seen echoed by other creators, not as medical advice. That framing matters when evaluating what she's actually claiming.

Does the science back this up?

On the menstrual cycle point, she is describing something real. The evidence on injection site variability is thinner, but not zero.

The hormonal fluctuation claim holds up reasonably well. Estrogen and progesterone shifts across the luteal phase are known to affect appetite-regulating hormones, including ghrelin. A 2021 review by Davidsen et al. in Obesity Reviews documented that progesterone-dominant phases of the cycle increase caloric intake and reduce satiety signaling. GLP-1 receptors interact with this system, so it is biologically plausible that GLP-1 medications feel less effective in the luteal phase. Plausible is not proven, but it is not made up either.

On injection sites, the pharmacokinetics data is more mixed. A 2014 study by Kapitza et al. in the Journal of Diabetes Science and Technology found that subcutaneous injection of liraglutide showed modest regional absorption differences between abdomen and thigh, but these differences were not clinically dramatic. There is no published trial specifically on tirzepatide injection site variability affecting weight outcomes. Sarah's claim here is based on anecdote, not controlled data.

What did they get wrong (or right)?

She got the cycle observation mostly right. The underlying biology supports why some users feel like GLP-1 medications are less effective in the luteal phase, and her advice to not judge a dose after one or two weeks is sensible and aligned with how these medications are actually titrated in clinical practice.

The injection site claim is where she overreaches. Saying there can be a "really big difference" based on creator observations and personal experience is not the same as evidence. Absorption differences between subcutaneous sites exist, but whether they translate into meaningful changes in weight loss or appetite suppression for tirzepatide specifically is not established. She does not cite anything, and the online GLP-1 community has a tendency to treat anecdote as protocol. That's worth flagging.

She also mispronounces both brand names, calling them "Mongaro" and "Wagovii." Small thing, but it does not inspire confidence when someone is presenting themselves as a resource for others navigating these medications.

What should you actually know?

If your GLP-1 dose increase is not delivering the results you expected, the most evidence-supported explanations include metabolic adaptation, dietary rebound as side effects ease, and yes, hormonal fluctuations tied to your cycle if you menstruate. A 2022 trial by Jastreboff et al. in The New England Journal of Medicine showed that tirzepatide's weight loss effects accumulate over months, not weeks, which supports Sarah's advice to wait before concluding a dose is not working.

On injection sites: rotating sites is recommended standard practice to prevent lipohypertrophy, which is scar tissue buildup that genuinely does impair absorption. So rotating is good practice regardless. But choosing thigh over abdomen because you read it works better is not something the clinical literature supports with confidence for this drug class.

• If you have PCOS, hormonal variability may affect how you experience GLP-1 medications across your cycle, though direct trial data on this is limited.
• Rotating injection sites is recommended to prevent tissue damage, not primarily to boost drug effectiveness.
• Do not judge a new dose level in under four weeks. Clinical titration schedules exist for a reason.
• Any changes to your injection routine or concerns about medication response should go through your prescribing clinician, not a TikTok comment section.